Kmt2a - lysine methyltransferase 2A Gene

Also Known as Mll; Mll1

Species: Rattus norvegicus

Gene Type: protein coding
Gene ID: 315606

Summary

Predicted to enable several functions, including lysine-acetylated histone binding activity; protein homodimerization activity; and protein methyltransferase activity. Involved in membrane depolarization and response to potassium ion. Predicted to be located in cytosol and nucleoplasm. Predicted to be part of MLL1 complex. Human ortholog(s) of this gene implicated in acute myeloid leukemia; cervical cancer; mixed phenotype acute leukemia; and non-Hodgkin lymphoma. Orthologous to human KMT2A (lysine methyltransferase 2A). [provided by Alliance of Genome Resources, Apr 2022]

Kmt2a Products (5)

mRNA Protein Name
XM_039082347.1 XP_038938275.1 histone-lysine N-methyltransferase 2A isoform X3
XM_039082346.1 XP_038938274.1 histone-lysine N-methyltransferase 2A isoform X2
XM_039082348.1 XP_038938276.1 histone-lysine N-methyltransferase 2A isoform X5
XM_008766179.2 XP_008764401.2 histone-lysine N-methyltransferase 2A isoform X4
XM_039082345.1 XP_038938273.1 histone-lysine N-methyltransferase 2A isoform X1

Gene Ontology

  • Biological Process
Biological Process GO Annotation Evidence References Source
involved in cellular response to transforming growth factor beta stimulus IMP
IMP: Inferred from mutant phenotype
31570196 RGD
involved in membrane depolarization IEP
IEP: Inferred from expression pattern
20211609 RGD
involved in positive regulation of gene expression IMP
IMP: Inferred from mutant phenotype
31570196 RGD
involved in protein modification process IMP
IMP: Inferred from mutant phenotype
34694864 RGD
involved in response to potassium ion IEP
IEP: Inferred from expression pattern
20211609 RGD
EXP: Inferred from Experiment IDA: Inferred from direct assay IPI: Inferred from physical interaction IMP: Inferred from mutant phenotype IGI: Inferred from genetic interaction IEP: Inferred from expression pattern
Protein Preferred Names Protein Names

histone-lysine N-methyltransferase MLL

histone-lysine N-methyltransferase 2A

  • Mixed-lineage leukemia (also acute lymphocytic leukemia 1 or trithorax Drosophila gene)

  • Mixed-lineage leukemia (also acute lymphocytic leukemia 1 or tritorax Drosophila gene)

  • lysine (K)-specific methyltransferase 2A

  • myeloid/lymphoid or mixed-lineage le

Related Agents

  • Clinical Phase
  • Pre-clinical Phase

Clinical Phase

Bioactive Molecules (1)
Cat. No. Product Name Effect
Purity Phase
HY-148669A Bleximenib oxalate 98.97% Phase 3

Pre-clinical Phase

Bioactive Molecules (10)
Cat. No. Product Name
Effect
Purity
Rare Diseases
HY-148669 Bleximenib 99.36% Unkown
HY-156794 Enzomenib Inhibitor 99.88% Unkown
HY-172416 Balomenib Inhibitor 99.81% Unkown
HY-148669B (S)-Bleximenib oxalate Control 98.37% Unkown
HY-156794A Enzomenib enantiomer Inhibitor 98.01% Unkown
HY-148829 MS40 Degrader / Unkown
HY-170832 Menin–KMT2A-IN-1 Inhibitor / Unkown
HY-RS07401 KMT2A Human Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS18528 Kmt2a Mouse Pre-designed siRNA Set A Pre-designed Set / Unkown
HY-RS25010 Kmt2a Rat Pre-designed siRNA Set A Pre-designed Set / Unkown

Orthologs Information

Species Symbol Source ID
Homo sapiens Kmt2a NCBI NCBI:4297